ATE516356T1 - Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung - Google Patents

Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung

Info

Publication number
ATE516356T1
ATE516356T1 AT02806841T AT02806841T ATE516356T1 AT E516356 T1 ATE516356 T1 AT E516356T1 AT 02806841 T AT02806841 T AT 02806841T AT 02806841 T AT02806841 T AT 02806841T AT E516356 T1 ATE516356 T1 AT E516356T1
Authority
AT
Austria
Prior art keywords
lysostaphin
staphylolytic
supported
improved
effect
Prior art date
Application number
AT02806841T
Other languages
English (en)
Inventor
Jeffrey Stinson
Lioubov Grinberg
Andrew Lees
James Mond
John Kokai-Kun
Original Assignee
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosynexus Inc filed Critical Biosynexus Inc
Application granted granted Critical
Publication of ATE516356T1 publication Critical patent/ATE516356T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02806841T 2001-12-21 2002-12-23 Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung ATE516356T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34180401P 2001-12-21 2001-12-21
PCT/US2002/040924 WO2003082184A2 (en) 2001-12-21 2002-12-23 Truncated lysostaphin molecule with enhanced staphylolytic activity

Publications (1)

Publication Number Publication Date
ATE516356T1 true ATE516356T1 (de) 2011-07-15

Family

ID=28675229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806841T ATE516356T1 (de) 2001-12-21 2002-12-23 Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung

Country Status (7)

Country Link
US (1) US20050118159A1 (de)
EP (1) EP1465990B1 (de)
JP (1) JP4348194B2 (de)
AT (1) ATE516356T1 (de)
AU (1) AU2002367820B2 (de)
CA (1) CA2469720A1 (de)
WO (1) WO2003082184A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734931A2 (de) * 2004-03-24 2006-12-27 Actavis Group Formulierungen von ramipril
CN100475965C (zh) * 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US11155801B2 (en) 2013-08-06 2021-10-26 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
WO2015175774A1 (en) 2014-05-14 2015-11-19 Trustees Of Dartmouth College Deimmunized lysostaphin and methods of use
CN106148254B (zh) * 2015-03-26 2019-11-12 南京华贞生物医药科技有限公司 一种用于减肥降脂的转化体及其构建方法与应用
CN107916244A (zh) * 2017-06-20 2018-04-17 江西嘉博生物工程有限公司 一种表达溶葡球菌素基因的重组乳酸乳球菌的构建方法及应用
CN111918960A (zh) * 2017-12-05 2020-11-10 比奥普来克斯有限公司 预防微生物感染的方法和组合物
KR20220163970A (ko) 2020-03-19 2022-12-12 마이크레오스 휴먼 헬스 비.브이. 안정화된 목적 단백질
CN115976158B (zh) * 2023-03-16 2023-07-04 百葵锐(天津)生物科技有限公司 一种裂解酶酶活性测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5011772A (en) * 1988-02-05 1991-04-30 Public Health Research Institute Of The City Of N.Y. High yield protein production system
DE4425645A1 (de) * 1994-07-20 1996-02-22 Mueller Karl & Co Kg Deletiertes Lysostaphingen von Staphylococcus simulans
CA2211293A1 (en) * 1997-07-23 1999-01-23 Immunova Ltee Recombinant lysostaphin analogs
US6028051A (en) * 1997-07-23 2000-02-22 Ambi Inc. Method for the treatment of staphylococcal disease
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
AU4706799A (en) * 1998-06-22 2000-01-10 University Of Vermont And State Agricultural College, The Treatment of (staphylococcus) infections
CN1267551C (zh) * 1999-10-19 2006-08-02 印度生物技术国际有限公司 重组成熟溶葡萄球菌素的表达
AU2001256350A1 (en) * 2000-05-12 2001-11-20 Bayer Aktiengesellschaft Regulation of human lysostaphin-like protease

Also Published As

Publication number Publication date
JP2005519628A (ja) 2005-07-07
WO2003082184A3 (en) 2004-07-22
AU2002367820B2 (en) 2007-11-01
EP1465990A2 (de) 2004-10-13
AU2002367820A1 (en) 2003-10-13
WO2003082184A2 (en) 2003-10-09
JP4348194B2 (ja) 2009-10-21
EP1465990B1 (de) 2011-07-13
CA2469720A1 (en) 2003-10-09
EP1465990A4 (de) 2006-06-28
US20050118159A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
TW200738261A (en) Stable protein formulations
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
ATE360031T1 (de) Chimäre proteine und anwendungen
AR032231A1 (es) Nuevas proteinas insecticidas de bacillus thuringiensis
NO20024157D0 (no) Kasein-avledete peptider og anvendelser derav i terapi
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
EA201001212A1 (ru) Лечение микробных инфекций
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
AU1922902A (en) Novel means for the diagnosis and therapy of CTCL
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
ATE516356T1 (de) Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
EE04938B1 (et) Orto-asendatud antraniilhappeamiidid ja nende kasutamine ravimitena
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
ATE310089T1 (de) Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen
BR112014023642A2 (pt) proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas
ATE412666T1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
WO2009037183A3 (de) Nukleinsäurehaltige kosmetische und/oder pharmazeutische zubereitung zur induktion antimikrobieller peptide in epithelialen deckgeweben
DE602006015103D1 (de) Als medikament geeignete lösliche varianten des gp130-moleküls

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties